(Q85158798)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

title

Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

main subject

phase II clinical trial

1 reference

1 reference

1 reference

Jorge A Garcia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Thomas E Hutson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Dale Shepard

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Paul Elson

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

Robert Dreicer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

publication date

4 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

page(s)

752-757

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Clinical pharmacology and pharmacogenetics of gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

A phase I study of gemcitabine and docetaxel for advanced stage solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Docetaxel in the management of prostate cancer: current standard of care and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25457

7 January 2021

Identifiers

DOI

10.1002/CNCR.25457

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20922803%20AND%20SRC:MED&resulttype=core&format=json

15 February 2020

1 reference